Generic Paxil Launches Unlikely This Year, Par Says; Court, FDA Issues
Executive Summary
Par does not expect generic competition to Paxil until a trial court rules on GlaxoSmithKline's patent infringement claims against other generic companies
You may also be interested in...
Generic Paxil Approved By FDA; Apotex Faces Tricky Launch Decision
Apotex faces an interesting calculation in determining whether and when to launch its generic version of Paxil
Paxil Regulatory Litigation May Affect Exclusivity, FDA “Ministerial” Role
Ivax' declaratory judgment actions against Paxil maker GlaxoSmithKline could threaten Apotex' 180-day exclusivity on paroxetine
Generic Paxil Approved By FDA; Apotex Faces Tricky Launch Decision
Apotex faces an interesting calculation in determining whether and when to launch its generic version of Paxil